![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
在复发性或耐火性多发性髓瘤中,特克利斯塔马布加达拉图穆马布
Luciano J Costa1, Nizar J Bahlis2, Aurore Perrot3
1Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham.
The New England journal of medicine
|December 9, 2025
概括
与标准疗法相比,tclistamab-daratumumab在多发性骨髓瘤患者中显著改善了无进展的生存期. 这种组合疗法显示出更高的整体应答率和最小的残留疾病负面影响.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 双特异性抗体Teclistamab针对CD3和B细胞成熟抗原,在复发性/耐药性多发性髓瘤中显示出前景.
- 达拉图马布是一种针对CD38的单克隆抗体,在多发性骨髓瘤患者中提供了生存益处.
研究的目的:
- 在患有多发性骨髓瘤的患者中,与基于daratumumab的疗法相比,评估teclistamab-daratumumab的疗效和安全性.
- 在第三阶段试验中,评估无进展生存率作为主要终点.
主要方法:
- 一项3期随机试验分配了先前接受过1至3次德克利斯塔马布-达拉图巴或达拉图巴加德克萨米他松与波马利多米德 (DPd) 或博尔特佐米布 (DVd) 治疗的患者.
- 无进展生存率由独立审查委员会评估.
主要成果:
- 德克利斯塔马布-达拉图穆马布的无进展生存时间显著更长 (83.4%在36个月),而不是DPd/DVd (29.7%).
- 较高的完全反应或更好的反应率 (81.8%与32.1%相比),整体反应 (89.0%与75.3%相比) 和MRD消极性 (58.4%与17.1%) 被观察到与teclistamab-daratumumab.
- 严重的不良事件报告在teclistamab-daratumumab组的70.7%,而DPd/DVd组的62.4%.
结论:
- 在多发性骨髓瘤患者中,德克利斯塔马布-达拉图穆马布在一到三次先前的治疗后显著提高了无进展的生存率.
- 组合疗法在治疗多发性骨髓瘤方面取得了重大进展.
相关概念视频
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:29Therapeutic Drug Monitoring: Affecting Factors
182
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
182